Weekly Stock Review: Baiao Tai (688177) BAT3306 combined with BAT8008 approved for clinical trials

NightAirdropper · 2026-04-05T12:23:16+00:00

As of April 3, 2026, Bio-Tai's stock price rose to 22.56 yuan, with a total market capitalization of 9.34B yuan. The company received approval for clinical trials and will conduct research on the combined treatment of advanced solid tumors using BAT3306 and BAT8008, facing risks and challenges.

NightAirdropper

2026-04-05 12:23:16

Abstract generation in progress

As of the close on April 3, 2026, BeiGene Biopharmaceutical (688177) closed at 22.56 yuan, up 1.21% from 22.29 yuan in the previous week. This week, BeiGene Biopharmaceutical’s intraday high on April 2 was 23.39 yuan. The intraday low on March 31 was 21.55 yuan. BeiGene Biopharmaceutical’s latest total market capitalization is 9.342 billion yuan, ranking 30/51 in the biopharmaceuticals products sector by market cap, and 2005/5193 among A-shares across both markets.

This Week’s Focus

Company announcement roundup: BAT3306 in combination with BAT8008 has received approval for a clinical trial

Company announcement roundup

Beijing Biotech Biopharmaceutical Co., Ltd. has recently received a “Notification of Approval for Drug Clinical Trial” issued and approved by the National Medical Products Administration, agreeing that the clinical trial of BAT3306 injection in combination with BAT8008 for injection in patients with advanced solid tumors will be conducted. BAT3306 is a biosimilar of pembrolizumab and is a PD-1 immune checkpoint inhibitor; BAT8008 is an antibody-drug conjugate (ADC) targeting Trop-2, which is intended for the treatment of solid tumors. This clinical trial still requires further research and approval before it can be marketed, and faces risks such as a long development cycle, high investment, and uncertain outcomes.

The above content has been compiled by Securities Star based on publicly available information and generated by an AI algorithm (Network Information Security Record No. 310104345710301240019), and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes